Retina Center of Texas | Southlake, TX

Research site
305 Morrison Park Drive Suite 100, Southlake, Texas, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


7 of 13
Status: Active
Trial type: Interventional
Funder type: Industry

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION)

Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DM...

Active, not recruiting
Diabetic Retinopathy
Drug: Intravitreal Ranibizumab 0.5 mg Injection
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary i...

Indeterminate Lesions
Ocular Melanoma
Device: Suprachoroidal Microinjector
Drug: Sham Treatment

This main long-term extension study is designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intr...

Active, not recruiting
Neovascular Age-related Macular Degeneration
Other: Sham Procedure
Drug: Faricimab

This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treat...

Diabetic Macular Edema
Drug: Faricimab

The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Ed...

Diabetic Macular Edema
Drug: foselutoclax
Drug: Aflibercept

Patients who completed Study ISEE2008 (GATHER2) and consent to participate will be administered monthly avacincaptad pegol 2 mg.

Active, not recruiting
Macular Degeneration
Geographic Atrophy
Drug: Avacincaptad pegol 2 mg intravitreal injection

Evaluate the effect of IONIS-FB-LRx on the rate of change of the area of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)...

Active, not recruiting
Macular Degeneration
Geographic Atrophy
Drug: Placebo

Trial conditions

Edema (6 trials)
Macular Edema (6 trials)
Macular Degeneration (5 trials)
Atrophy (3 trials)
Diabetic Retinopathy (3 trials)
Geographic Atrophy (3 trials)
Retinal Diseases (2 trials)
Wet Macular Degeneration (2 trials)
Eye Diseases (1 trial)
Melanoma (1 trial)

And 1 more

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems